Abstract Perspective: Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts


“In March 2020, there was a debate over whether non-steroidal anti-inflammatory drugs (NSAIDs) may worsen the prognosis of COVID-19. Working on behalf of NHS England, we conducted two cohort studies using routine clinical data in England linked to death data within the OpenSAFELY platform. We compared the risk of COVID-19 related death among people who were currently prescribed NSAIDs as part of their routine clinical care, with those who were not. We also further investigated whether the association varied by type of NSAIDs such as different doses of naproxen, ibuprofen or COX-2 specific NSAIDs. We found no evidence of a higher risk of COVID-19 related death associated with routinely use of NSAIDs. Similarly, we found no evidence of an increased risk of COVID-19 related death associated with ibuprofen, different doses of naproxen nor COX-2 specific NSAIDs. In conclusion, people currently prescribed NSAIDs for their long-term conditions should continue their treatment as part of their routine care.”

– Study author Angel Wong, PhD